Breast Cancer

Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response

Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response

By

Existing studies that summarize the risks of breast implants are not adequately powered to detect all harms, alleged authors of a study including nearly 100,000 patient outcomes.

Talazoparib Found to Confer a Survival Advantage in <I>BRCA1/2</i>-Positive Breast Cancer

Talazoparib Found to Confer a Survival Advantage in BRCA1/2-Positive Breast Cancer

By

Oral treatment with talazoparib improved progression-free survival and some quality of life measures compared with standard chemotherapy.

<i>BRCA1</i>/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors

BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors

By

Double mutants may predict resistance to PARP inhibitors and could also indicate sensitivity to alternative treatments.

Beyond <I>BRCA</i>: New Predisposition Genes Linked to Breast, Ovarian Cancers

Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers

By

Whole-exome sequencing revealed that PALB2, ATM, CHEK2, and MSH6 genes were significantly associated with an increased risk of breast cancer; MSH6, RAD51C, TP53, and ATM were found to be linked to an increased risk of ovarian cancer.

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

By

More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.

Identifying Gene Variants Involved in Radiotherapy Toxicity Risk: A Q&A With Benjamin Smith, MD

Identifying Gene Variants Involved in Radiotherapy Toxicity Risk: A Q&A With Benjamin Smith, MD

By

Genomics could guide the decision about whether a patient should undergo implant reconstruction or autologous tissue-based reconstruction.

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

By

There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.

Breast Cancer Subtype May Be Predictive of Ipsilateral Breast Tumor Recurrence

Breast Cancer Subtype May Be Predictive of Ipsilateral Breast Tumor Recurrence

By

Radiotherapy after surgery may modify ipsilateral breast tumor recurrence risk among different subtypes of breast cancer.

Radiofrequency Ablation Plus Surgery May Improve Tumor Control in Early-Stage Breast Cancer

Radiofrequency Ablation Plus Surgery May Improve Tumor Control in Early-Stage Breast Cancer

By

Whether radiofrequency ablation is a superior treatment option to lumpectomy requires further investigation.

High BMI Linked With Lower Breast Cancer Risk in Premenopausal Women

High BMI Linked With Lower Breast Cancer Risk in Premenopausal Women

By

Having a high body mass index reduces the risk for developing breast cancer before menopause, but more research is needed to understand the biological mechanism.

Bispecific Antibodies in Cancer

Bispecific Antibodies in Cancer

By

Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.

Religion, Spirituality, May Influence Physical Health Outcomes in Survivors of Breast Cancer

Religion, Spirituality, May Influence Physical Health Outcomes in Survivors of Breast Cancer

By

The role and impact of religiousness/spirituality in determining physical well-being among survivors of breast cancer is not well understood.

Copy Number Abnormalities May Inform Survival, Drug Resistance

Copy Number Abnormalities May Inform Survival, Drug Resistance

By

For cancers associated with numerous copy number changes, it is difficult to assign disease classifiers and identify useful targets for drug development.

High-Risk Breast Cancer Patients May Not Be Adherent to Heart Failure Monitoring

High-Risk Breast Cancer Patients May Not Be Adherent to Heart Failure Monitoring

By

There is a paucity of data regarding the cardiotoxicity and the monitoring adherence habits of patients undergoing treatment with trastuzumab or anthracyclines, commonly used therapies among patients with HER2-positive breast cancer.

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

By

Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.

Breast Cancer (Invasive) Treatment Regimens

The latest breast cancer treatment regimens with detailed drug information such as pertuzamab with trastuzumab and docetaxel.

Ribociclib FDA-Approved For Additional Indications in HR+, HER2- Advanced Breast Cancer

Ribociclib FDA-Approved For Additional Indications in HR+, HER2- Advanced Breast Cancer

By

The FDA based its approval on the results of a triplet of phase 3 studies, the MONALEESA-2, MONALEESA-3, and MONALEESA-7.

Triclosan and Cancer Risk: Is There a Link?

Triclosan and Cancer Risk: Is There a Link?

By

Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.

Aggressive Follow-Up Imaging in Breast Cancer Is Geography-Specific

Aggressive Follow-Up Imaging in Breast Cancer Is Geography-Specific

By

Variations in the use and frequency of advanced imaging post-surgery in patients with breast cancer were observed across regions of the United States.

FDA-Approved Breast Cancer Drug Treatments

Treatment chart with usual dosage, strength, and formulation of FDA approved medications for breast cancer.

Adding Ovarian Suppression May Improve Survival Outcomes in Premenopausal Breast Cancer

Adding Ovarian Suppression May Improve Survival Outcomes in Premenopausal Breast Cancer

By

Updated results of the SOFT and TEXT trial suggest that adding ovarian suppression to exemestane or tamoxifen could improve survival outcomes.

Tucatinib May Be A Safe, Novel Treatment for <i>ERBB2/HER2</i>-Positive Breast Cancer

Tucatinib May Be A Safe, Novel Treatment for ERBB2/HER2-Positive Breast Cancer

By

For this phase 1b study, researchers enrolled 57 patients with ERBB2/HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.

Is Genomic Medicine Failing Minority Patients?

Is Genomic Medicine Failing Minority Patients?

By

Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.

Trastuzumab Retreatment May Be Safe and Effective in Breast Cancer Recurrence

Trastuzumab Retreatment May Be Safe and Effective in Breast Cancer Recurrence

By

The effectiveness of trastuzumab in retreating patients with recurrence who received it during perioperative therapy is the focus of a new study.

Do the Risks of Direct-to-Consumer Testing Outweigh the Benefits?

Do the Risks of Direct-to-Consumer Testing Outweigh the Benefits?

By

There are benefits and drawbacks to the public availability to DTC mutation tests.

<i>ARID1A</i> Mutations Might Predict Tumor Response to Immunotherapy

ARID1A Mutations Might Predict Tumor Response to Immunotherapy

By

New findings bolster the case for the predictive utility of ARID1A mutations.

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

By

A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

By

Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

By

Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.

Six-Month Trastuzumab Sufficient for HER2-Positive Early Stage Breast Cancer

Six-Month Trastuzumab Sufficient for HER2-Positive Early Stage Breast Cancer

By

Assignment to 6 months of adjuvant trastuzumab was non-inferior to 12 months trastuzumab in women with HER2-positive, early breast cancer.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs